Biotest AG (BIO3.DE)
28.90
-0.30 (-1.03%)
At close: Mar 13, 2025, 4:30 PM
-1.03% (1D)
| Bid | 29 |
| Market Cap | 1.37B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | 1.73 |
| PE Ratio (ttm) | 16.71 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | 29.5 |
| Volume | 318 |
| Avg. Volume (20D) | 4,893 |
| Open | 28.90 |
| Previous Close | 29.20 |
| Day's Range | 28.70 - 28.90 |
| 52-Week Range | 22.80 - 29.90 |
| Beta | 0.26 |
About BIO3.DE
Biotest Aktiengesellschaft develops, manufactures, and sells biological medicines in Germany and internationally. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in hematology, clinical immunology, and intensive care medicine areas. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophyl...
Industry Biotechnology
Sector Healthcare
IPO Date Nov 17, 1998
Employees 2,426
Stock Exchange XETRA
Ticker Symbol BIO3.DE
Website https://www.biotest.com